Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-jwnkl Total loading time: 0 Render date: 2024-07-09T10:26:35.386Z Has data issue: false hasContentIssue false

Chapter 8 - Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease

from Section I - The Pharmacological Basis for Parkinson's Disease Treatment

Published online by Cambridge University Press:  05 March 2016

By
Ilana Schlesinger  and
Amos D. Korczyn
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 76 - 82
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Korczyn, AD, Keren, O. The effect of dopamine on the papillary diameter in mice. Life Sci 1980; 26: 757–63.CrossRefGoogle Scholar
Korczyn, AD. Pathophysiology of drug-induced dyskinesias. Neuropharmacology 1973; 11: 601–7.Google Scholar
Routtinen, HM, Rinne, UK. Entacapone prolongs levodopa response in one-month double-blind study in Parkinsonian patients with levodopa-related fluctuations. J Neurol Neurosurg Psychiatry 1996; 60: 36–40.Google Scholar
Ceravalo, R, Piccini, P, Bailey, DL, et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002; 43: 201–7.Google Scholar
Jorga, KM. COMT inhibitors: pharmacokinetics and pharmacodynamic comparisons. Clin Neuropharmacol 1998; 21 (Suppl.): S9–16.Google Scholar
Corvol, JC, Bonnet, C, Charbonnier-Beaupel, F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011; 69: 111–8.CrossRefGoogle ScholarPubMed
Maltête, D, Cottard, AM, Mihout, B, Costentin, J. Erythrocytes catechol-O-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients. Clin Neuropharmacol 2011; 34: 21–3.CrossRefGoogle ScholarPubMed
Agid, Y, Destée, A, Durif, F, et al. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group. Lancet 1997; 350: 712–13.Google Scholar
Baas, H, Beiske, AG, Ghika, J. COMT inhibitors with tolcapone reduces ‘wearing-off’ phenomenon and levodopa requirements in fluctuating Parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421–8.CrossRefGoogle Scholar
Adler, CH, Singer, C, O'Brien, C., et al. Randomized placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa carbidopa. Arch Neurol 1998; 55: 1089–95.Google Scholar
Brooks, DJ, Sagar, H, UK–Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients in Parkinson's disease: a randomized, placebo controlled, double-blind, six months study. J Neurol Neurosurg Psychiatry 2003; 74: 1071–9.Google Scholar
Fenelon, G, Gimenez-Roldan, S, Monstrut, JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 2008; 110: 239–51.Google Scholar
Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747–55.Google Scholar
Myllylä, VV, Kultalahti, ER, Haapaniemi, H, Leinonen, M, FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001; 8: 53–60.CrossRefGoogle ScholarPubMed
Larsen, JP, Worm-Petersen, J, Sideo, A, et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2008; 10: 137–46.Google Scholar
Rinne, UK, Larsen, JP, Siden, A, et al. Entacapone enhances the response to levodopa in Parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309–14.Google Scholar
Stocchi, F, Rascol, O, Kieburtz, K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early PD: the STRIDE-PD study. Ann Neurol 2010; 68: 18–27.Google Scholar
Fox, SH, Katzenschlager, R, Lim, SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 3): S2–41.Google Scholar
US FDA. FDA Drug Safety Communication: ongoing safety review of Stalevo (entacapone/carbidopa/levodopa) and possible development of prostate cancer. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm206363.htm.Google Scholar
Zesiewicz, TA, Wecker, L, Sullivan, KL, Merlin, LR, Hauser, RA. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006; 29: 106–11.Google Scholar
Stowe, R, Ives, N, Clarke, CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011; 26: 587–98.CrossRefGoogle ScholarPubMed
Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007; 22: 14–19.CrossRefGoogle Scholar
Valeant Pharmaceuticals. TASMAR® (tolcapone). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf.Google Scholar
Ferreira, JJ, Rascol, O, Poewe, W, et al. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci Ther 2010; 16: 337–47.CrossRefGoogle ScholarPubMed
Korczyn, AD, Nisipeanu, P, Newer therapies for Parkinson's disease. Neurol Neurochir Pol 1996; 30 (Suppl. 2): 105–11.Google Scholar
Inzelberg, R, Nisipeanu, P, Rabey, JM, et al. Double-blind comparison of caberigolineand bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996; 47: 785–8.CrossRefGoogle ScholarPubMed
Rascol, O, Brooks, DJ, Korczyn, AD, et al. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levidopa. N Engl J Med 2000; 342: 1484–91.Google Scholar
Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721–8.Google Scholar
Korczyn, AD. Transdermal therapy in Parkinson's disease. Lancet Neurol 2007; 6: 475–6.Google Scholar
Kurth, MC, Adler, CH, Saint Hilaire, MH. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48: 81–7.Google Scholar
Rajput, AH, Martin, W, Saint Hilaire, MH, Dorflinger, E, Pedder, S. Tolcapone improves motor function in Parkinsonian patients with the ‘wearing-off’ phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066–71.CrossRefGoogle ScholarPubMed
Rabey, M, Sagi, I, Huberman, M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease. Clin Neuropharmacol 2000; 23: 324–30.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×